Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2009)
for the PARR-2 Investigators
K. Allman, L. Shaw, R. Hachamovitch, J. Udelson (2002)
Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.Journal of the American College of Cardiology, 39 7
L. Ling, T. Marwick, D. Flores, W. Jaber, R. Brunken, M. Cerqueira, R. Hachamovitch (2013)
Identification of Therapeutic Benefit from Revascularization in Patients With Left Ventricular Systolic Dysfunction: Inducible Ischemia Versus Hibernating MyocardiumCirculation: Cardiovascular Imaging, 6
B. Gerber, M. Rousseau, Sylvie Ahn, J. Waroux, A. Pouleur, T. Phlips, D. Vancraeynest, A. Pasquet, J. Vanoverschelde (2012)
Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy.Journal of the American College of Cardiology, 59 9
P. Pagley, G. Beller, D. Watson, L. Gimple, M. Ragosta (1997)
Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability.Circulation, 96 3
(2011)
Rouleau JL; STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction
D. Shearn, B. Brent (1986)
Coronary artery bypass surgery in patients with left ventricular dysfunction.The American journal of medicine, 80 3
Yoichi Inaba, Jennifer Chen, S. Bergmann (2010)
Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysisJournal of Nuclear Cardiology, 17
R. Beanlands, G. Nichol, E. Huszti, D. Humen, N. Racine, M. Freeman, K. Gulenchyn, L. Garrard, R. deKemp, Ann Guo, T. Ruddy, F. Bénard, A. Lamy, R. Iwanochko (2007)
F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).Journal of the American College of Cardiology, 50 20
A. Schinkel, Jeroen Bax, D. Poldermans, A. Elhendy, R. Ferrari, S. Rahimtoola (2007)
Hibernating myocardium: diagnosis and patient outcomes.Current problems in cardiology, 32 7
R. Kim, E. Wu, Allen Rafael, Enn‐ling Chen, M. Parker, O. Simonetti, F. Klocke, R. Bonow, R. Judd (2000)
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.The New England journal of medicine, 343 20
R. Bonow, G. Maurer, Kerry Lee, T. Holly, P. Binkley, P. Desvigne‐Nickens, J. Drożdż, P. Farsky, A. Feldman, T. Doenst, R. Michler, D. Berman, J. Nicolau, P. Pellikka, Krzysztof Wróbel, N. Alotti, F. Asch, L. Favaloro, Lilin She, E. Velazquez, Robert Jones, J. Panza (2011)
Myocardial viability and survival in ischemic left ventricular dysfunction.The New England journal of medicine, 364 17
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 62 16
A. Abraham, G. Nichol, K. Williams, Ann Guo, R. deKemp, L. Garrard, R. Davies, L. Duchesne, H. Haddad, B. Chow, J. DaSilva, R. Beanlands (2010)
18F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to 18F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 TrialJournal of Nuclear Medicine, 51
(2011)
STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction
Editorials ◼ coronary revascularization ◼ hibernating myocardium ◼ medical therapy ◼ positron emission tomography
Editorial More Evidence for the Survival Benefit of Coronary Revascularization Versus Medical Therapy in Patients With Ischemic Cardiomyopathy and Hibernating Myocardium George A. Beller, MD or many years, it has been recognized that patients Article see p 363 Fwith coronary artery disease (CAD) and left ventricu- All the noninvasive viability imaging techniques in clinical lar (LV) dysfunction who manifest substantial myocardial use can adequately identify hibernating myocardium in patients viability in asynergic myocardial regions have improved LV with ischemic cardiomyopathy. When the relative sensitivities regional and global function, exhibit reverse LV remodel- and specificities of these modalities are compared, PET-FDG ing, and exhibit a reduction in ischemic mitral regurgitation had the highest sensitivity and dobutamine echocardiography and a reduction in heart failure symptoms after revascular- had the highest specificity for detection of viability. A meta- ization. Observational studies using a variety of noninvasive analysis was conducted to determine the optimal cutoff values methodologies for assessment of myocardial viability have for the assessment of viability using these various imaging also shown enhanced survival with revascularization versus techniques for which revascularization would offer a survival medical therapy in such patients. A much quoted meta-anal- benefit in patients with ischemic cardiomyopathy. The
Circulation: Cardiovascular Imaging – Wolters Kluwer Health
Published: May 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.